

Massy – July 7th 2014


Professor Pierre Corvol appointed Chairman of the Scientific Advisory Board of Quantum Genomics

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the appointment of Professor Pierre Corvol as Chairman of its Scientific Advisory Board.

Pierre Corvol is a specialist of the renin-angiotensin system. He discovered the major role of this system in the regulation of arterial blood pressure. His works were at the origin of the treatment of cardiovascular diseases with inhibitors of the renin system.

The advisory board will be composed international scientific experts in the field of cardiology. It will provide recommendations for the research and development programs of Quantum Genomics and address in particular the question of relevant biomarkers for resistant hypertension and congestive heart failure

The other members will be announced in September 2014.



Pierre Corvol

Professor Emeritus at Collège de France

Honorary Director of Collège de France

Member of the Academy of Sciences

Member of the Academy of Medicine

Member of the American Academy of Arts and Sciences

Pierre Corvol, medical doctor, is Professor Emeritus at Collège de France and honorary director of Collège de France. He headed the high blood pressure service of the Broussais Hospital (1986 -1999) and was director of the Inserm unit of Vascular and renal endocrinology pathology (1982-2006). He was Professor at Collège de France (Chair of Experimental Medicine) from 1989 to 2012.

His research was focused on the study of hormonal mechanisms of regulating blood pressure. He established the crucial role of the renin - angiotensin - aldosterone system

in the regulation of renal and cardiac function. The work of his team has contributed to the development of treatments commonly used to treat high blood pressure and cardiovascular diseases.

He conducted the first studies on the genetics of human hypertension. He recently worked on angiogenesis and the remodelling of the arterial wall in cardiovascular pathologies.

He is a member of the Academy of Sciences, the Academy of Medicine and the American Academy of Arts and Sciences. He has received numerous awards including the Ciba Award for Hypertension Research (1985) and the Grand Prix Inserm (2006). Main publications (from over 732): cloning of renin and angiotensin converting enzyme (Nature, 1982; PNAS, 1988); Molecular genetics of human hypertension (Cell, 1992); Functional consequences of inactivating mutations of the renin system in humans (Human Mol. Genetics, 2011 and 2013).

Pierre Corvol is appointed Chairman of the Scientific Advisory Board of Quantum Genomics for a period of 4 years.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.

Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).

Contacts

Quantum Genomics

Lionel Ségard
CEO
(+33) 1 60 13 76 80

Quantum Genomics

Marc Karako
CFO - Investor relations
(+33) 1 60 13 76 84
marc.karako@quantum-genomics.com

ACTUS

Jean-Michel Marmillon
Press relations
(33) 1 53 67 07 80
jmmarmillon@actus.fr
